Login to Your Account

Ethris hooks big pharma partner in five-year mRNA discovery deal

By Nuala Moran
Staff Writer

Monday, August 21, 2017

LONDON – Ethris GmbH sealed a five-year agreement with Astrazeneca plc and its Medimmune biologics subsidiary for the discovery of messenger RNA therapeutics for treating pulmonary diseases.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription